CD28 Down-Regulation on Circulating CD4 T-Cells Is Associated with Poor Prognoses of Patients with Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Although the etiology of idiopathic pulmonary fibrosis (IPF) remains perplexing, adaptive immune activation is evident among many afflicted patients. Repeated cycles of antigen-induced proliferation cause T-cells to lose surface expression of CD28, and we hypothesized this process might also occur in IPF. METHODOLOGY/PRINCIPAL FINDINGS: Peripheral blood CD4 T-cells from 89 IPF patients were analyzed by flow cytometry and cytokine multiplex assays, and correlated with clinical events. In comparison to autologous CD4(+)CD28(+)cells, the unusual CD4(+)CD28(null) lymphocytes seen in many IPF patients had discordant expressions of activation markers, more frequently produced cytotoxic mediators perforin (2.4+/-0.8% vs. 60.0+/-7.4%, p<0.0001) and granzyme B (4.5+/-2.8% vs.74.9+/-6.5%, p<0.0001), produced greater amounts of many pro-inflammatory cytokines, and less frequently expressed the regulatory T-cell marker FoxP3 (12.9+/-1.1% vs. 3.3+/-0.6% p<0.0001). Infiltration of CD4(+)CD28(null) T-cells in IPF lungs was confirmed by confocal microscopy. Interval changes of CD28 expression among subjects who had replicate studies were correlated with conterminous changes of their forced vital capacities (r(s) = 0.49, p = 0.012). Most importantly, one-year freedom from major adverse clinical events (either death or lung transplantation) was 56+/-6% among 78 IPF patients with CD4(+)CD28(+)/CD4(total)>or=82%, compared to 9+/-9% among those with more extensive CD28 down-regulation (CD4(+)CD28(+)/CD4(total)<82%) (p = 0.0004). The odds ratio for major adverse events among those with the most extensive CD28 down-regulation was 13.0, with 95% confidence intervals 1.6-111.1. CONCLUSIONS/SIGNIFICANCE: Marked down-regulation of CD28 on circulating CD4 T-cells, a result of repeated antigen-driven proliferations, is associated with poor outcomes in IPF patients. The CD4(+)CD28(null) cells of these patients have potentially enhanced pathogenic characteristics, including increased productions of cytotoxic mediators and pro-inflammatory cytokines. These findings show proliferative T-cell responses to antigen(s) resulting in CD28 down-regulation are associated with progression and manifestations of IPF, and suggest assays of circulating CD4 T-cells may identify patients at greatest risk for clinical deterioration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






![Figure 7 Flow cytometry methodology (see also references 20, 52). Aliquots of fresh, live peripheral blood mononuclear cells (PBMNC) were stained with anti-CD4-allophycocyanin (APC), anti-CD28-fluorescein isothiocyanate (FITC), and phycoerythrin (PE)-conjugated antibodies against other cell epitopes. A.) Ten thousand (10,000) or more live cells were selected for further study, based their side scatter (SSC) and forward scatter (FSC) characteristics (G1). B.) The brightly staining CD4 cells among these also expressed CD3 (Cy-Chrome) and, thus, are T-cells [52]. C.) These CD4 T-cells were further characterized based on their expression of CD28. The proportions of CD4+CD28+ T-cells among the total CD4+ T-cell population (upper left and upper right quadrants) defines the CD28%. The respective proportions of CD4+CD28+ and CD4+CD28null cells that co-expressed other cell determinants of interest (in this case MHC Class II [DR]) were quantitated. Numbers within the delineated region/quadrants denote the proportions of cells with these respective characteristics.](https://figures.cochat.ai/paper-figures/974f8f991dff4f4c9356985eebda3f1e/cd28-down-regulation-on-circulating-cd4-t-cells-is-associated-with-poor-figure-7.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“reduced expression of the costimulatory molecule CD28 on circulating T cells was seen to be a predictor of poor outcomes (130).”
From The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis (2018) · cites this paper as [130]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sakaguchi, S. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141122 · Cited by 3,306 · cited 1×
“(Treg), widely regarded as having important roles in dampening adaptive immune responses against antigens [16], are diminished in both the circulation and broncholavolar lavage returns of IPF patients [17].”
BackgroundIdiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Sharpe, A. H., & Freeman, G. J. (2002) · Nature Reviews Immunology · doi:10.1038/nri727 · Cited by 1,712 · cited 2×
“Nearly all normal CD4 T-lymphocytes express CD28 on their cell surfaces [38], and finding significant proportions of circulating CD4CD28 T-cells is distinctly abnormal [19–34].”
BackgroundIdiopathic Pulmonary Fibrosis: Clinical Relevance of Pathologic Classification
KATZENSTEIN, A.-L. A., & MYERS, J. L. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.4.9707039 · Cited by 1,261
Editorial: Cerebral Palsy—the International Consensus Statement
Clements, R. V., & Simanowitz, A. (2000) · Clinical Risk · doi:10.1177/135626220000600401 · Cited by 856
international consensus statement
Clements, R. V., & Simanowitz, A. (2000) · Cited by 852
Changes in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Tai, X., Cowan, M., Feigenbaum, L., & Singer, A. (2005) · Nature Immunology · doi:10.1038/ni1160 · Cited by 613
Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes.
Liuzzo, G., Goronzy, J. J., Yang, H., Kopecky, S. L., Holmes, D. R., Frye, R. L., & Weyand, C. M. (2000) · Circulation · doi:10.1161/01.cir.101.25.2883 · Cited by 552 · cited 10×
“These data demonstrate that the CD4CD28 T-cells of IPF patients exhibit unusual characteristics (Figure 1B and Figure 2) that are very similar to analogous cells isolated from other patient populations with chronic immunologic diseases [19–34].”
BackgroundResultInfluentialSallusto, F., & Lanzavecchia, A. (2000) · Immunological Reviews · doi:10.1034/j.1600-065x.2000.17717.x · Cited by 523
The bacterial superantigen and superantigen‐like proteins
Fraser, J. D., & Proft, T. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00681.x · Cited by 495 · cited 1×
“Microbial superantigens are among the most potent antigens known, can mediate life-threatening toxic shock syndrome, and activate , 2 20% of total T-cells among infected individuals [48].”
BackgroundSchmidt, D., Goronzy, J. J., & Weyand, C. M. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118638 · Cited by 482
T-cell-mediated lysis of endothelial cells in acute coronary syndromes
Nakajima, T., Schulte, S., Warrington, K. J., Kopecky, S. L., Frye, R. L., Goronzy, J. J., & Weyand, C. M. (2002) · Circulation · doi:10.1161/hc0502.103348 · Cited by 356
Expansion of unusual CD4+ T cells in severe rheumatoid arthritis
Martens, P. B., Goronzy, J. J., Schaid, D., & Weyand, C. M. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400615 · Cited by 290 · cited 10×
“These data demonstrate that the CD4CD28 T-cells of IPF patients exhibit unusual characteristics (Figure 1B and Figure 2) that are very similar to analogous cells isolated from other patient populations with chronic immunologic diseases [19–34].”
BackgroundResultInfluentialKitani, A., Fuss, I., Nakamura, K., Kumaki, F., Usui, T., & Strober, W. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030917 · Cited by 260
T-Lymphocyte-Antigen Interactions in Transplant Rejection
Epstein, F. H., Krensky, A. M., Weiss, A., Crabtree, G., Davis, M. M., & Parham, P. (1990) · New England Journal of Medicine · doi:10.1056/nejm199002223220805 · Cited by 255
Distribution of lymphocyte subsets and natural killer cells in the human body
Westermann, J., & Pabst, R. (1992) · The Clinical Investigator · doi:10.1007/bf00184787 · Cited by 248 · cited 1×
“Since the circulating T-cell compartment represents only a miniscule fraction of the lymphocytes that traffic from inflamed tissue and proximate lymph nodes [45,46], the total numbers of these highly altered lymphocytes in the IPF patients is incalculably large.”
BackgroundIdiopathic Pulmonary Fibrosis: Pathogenesis and Therapeutic Approaches
Selman, M., Thannickal, V. J., Pardo, A., Zisman, D. A., Martinez, F. J., & Lynch, J. P. (2004) · Drugs · doi:10.2165/00003495-200464040-00005 · Cited by 244
IL-10, an inflammatory/inhibitory cytokine, but not always
Conti, P., Kempuraj, D., Kandere, K., Gioacchino, M. D., Barbacane, R. C., Castellani, M. L., Felaco, M., Boucher, W., Letourneau, R., & Theoharides, T. C. (2003) · Immunology Letters · doi:10.1016/s0165-2478(03)00002-6 · Cited by 235 · cited 1×
“The comparatively lesser production of IL-10 by CD4CD28 cells may have particular biologic importance in fibrotic disorders, given the possible roles of this cytokine in general suppression of deleterious immune responses [42] and inhibition of TGF-bmediated fibrogenesis [43].”
BackgroundGlobal impairment of CD4+CD25+FOXP3+ regulatory T cells in idiopathic pulmonary fibrosis
Kotsianidis, I., Nakou, E., Bouchliou, I., Tzouvelekis, A., Spanoudakis, E., Steiropoulos, P., Sotiriou, I., Aidinis, V., Margaritis, D., Tsatalas, C., et al. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200812-1936oc · Cited by 230
Barbas-Filho, J. V., Ferreira, M. A., Sesso, A., Kairalla, R. A., Carvalho, C. R. R., & Capelozzi, V. L. (2001) · Journal of Clinical Pathology · doi:10.1136/jcp.54.2.132 · Cited by 229
Vallejo, A. N., Weyand, C. M., & Goronzy, J. J. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.01.002 · Cited by 223 · cited 5×
“As such, and amongst other possibilities, the ability to generate CD4CD28 cells with repeated/chronic antigen engagements could conceivably represent an evolutionary adaptation to more effectively counter difficult-to-eradicate microbial pathogens [19].”
BackgroundInfluentialKomocsi, A., Lamprecht, P., Csernok, E., Mueller, A., Holl-Ulrich, K., Seitzer, U., Moosig, F., Schnabel, A., & Gross, W. L. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61118-2 · Cited by 206 · cited 10×
“These data demonstrate that the CD4CD28 T-cells of IPF patients exhibit unusual characteristics (Figure 1B and Figure 2) that are very similar to analogous cells isolated from other patient populations with chronic immunologic diseases [19–34].”
BackgroundResultInfluentialSchirmer, M., Vallejo, A. N., Weyand, C. M., & Goronzy, J. J. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.2.1018 · Cited by 191 · cited 9×
“These data demonstrate that the CD4CD28 T-cells of IPF patients exhibit unusual characteristics (Figure 1B and Figure 2) that are very similar to analogous cells isolated from other patient populations with chronic immunologic diseases [19–34].”
BackgroundMethodResultInfluentialEarly Interstitial Lung Disease in Familial Pulmonary Fibrosis
Rosas, I. O., Ren, P., Avila, N. A., Chow, C. K., Franks, T. J., Travis, W. D., McCoy, J. P., May, R. M., Wu, H.-P., Nguyen, D. M., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200702-254oc · Cited by 180 · cited 1×
“infiltrate into IPF lungs prior to development of symptoms [14],”
BackgroundMarchal-Sommé, J., Uzunhan, Y., Marchand-Adam, S., Valeyre, D., Soumelis, V., Crestani, B., & Soler, P. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.10.5735 · Cited by 179
Prognostic markers of radiographic progression in early rheumatoid arthritis
Goronzy, J. J., Matteson, E. L., Fulbright, J. W., Warrington, K. J., Chang‐Miller, A., Hunder, G. G., Mason, T. G., Nelson, A. M., Valente, R. M., Crowson, C. S., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.11445 · Cited by 170
Cellular and Humoral Autoreactivity in Idiopathic Pulmonary Fibrosis
Feghali-Bostwick, C. A., Tsai, C. G., Valentine, V. G., Kantrow, S., Stoner, M. W., Pilewski, J. M., Gadgil, A., George, M. P., Gibson, K. F., Choi, A. M. K., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.4.2592 · Cited by 160
Self-citationFasth, A. E. R., Dastmalchi, M., Rahbar, A., Salomonsson, S., Pandya, J. M., Lindroos, E., Nennesmo, I., Malmberg, K.-J., Söderberg-Nauclér, C., Trollmo, C., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803688 · Cited by 157
Heat-Shock Protein 60-Reactive CD4 + CD28 null T Cells in Patients With Acute Coronary Syndromes
Zal, B., Kaski, J. C., Arno, G., Akiyu, J. P., Xu, Q., Cole, D., Whelan, M., Russell, N., Madrigal, J. A., Dodi, I. A., et al. (2004) · Circulation · doi:10.1161/01.cir.0000118476.29352.2a · Cited by 156
Monaco, C., Andreakos, E., Kiriakidis, S., Feldmann, M., & Paleolog, E. (2004) · Current Drug Target -Inflammation & Allergy · doi:10.2174/1568010043483881 · Cited by 138
Scheibenbogen, C., Romero, P. J., Rivoltini, L., Herr, W., Schmittel, A. H., Cerottini, J., Woelfel, T., Eggermont, A. M. M., & Keilholz, U. (2000) · Journal of Immunological Methods · doi:10.1016/s0022-1759(00)00257-x · Cited by 133
Lung Transplantation for Idiopathic Pulmonary Fibrosis
Mason, D. P., Brizzio, M. E., Alster, J. M., McNeill, A. M., Murthy, S. C., Budev, M. M., Mehta, A. C., Minai, O. A., Pettersson, G., & Blackstone, E. H. (2007) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2007.04.096 · Cited by 131
Dendritic Cells Accumulate in Human Fibrotic Interstitial Lung Disease
Marchal-Sommé, J., Uzunhan, Y., Marchand-Adam, S., Kambouchner, M., Valeyre, D., Crestani, B., & Soler, P. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200609-1347oc · Cited by 123 · cited 1×
“and pro-inflammatory dendritic cells accumulate in the pulmonary parenchyma of advanced cases [15].”
BackgroundKurosu, K., Takiguchi, Y., Okada, O., Yumoto, N., Sakao, S., Tada, Y., Kasahara, Y., Tanabe, N., Tatsumi, K., Weiden, M., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.1.756 · Cited by 111 · cited 1×
“None had ongoing acute exacerbations of IPF [3], clinical or serologic evidence of autoimmune disorders, malignancies, or concurrent infections.”
BackgroundPeripheral T Cell Functions Correlate with the Severity of Chronic Obstructive Pulmonary Disease
Zhu, X., Gadgil, A. S., Givelber, R. J., George, M. P., Stoner, M. W., Sciurba, F. C., & Duncan, S. R. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802622 · Cited by 108
Self-citationIdiopathic Pulmonary Fibrosis Related to Endothelial Injury and Antiendothelial Cell Antibodies
MAGRO, C. M. J., Waldman, W. J., Knight, D. A., Allen, J. N., Nádasdy, T., Frambach, G. E., Ross, P., & Marsh, C. B. (2006) · Human Immunology · doi:10.1016/j.humimm.2006.02.026 · Cited by 100 · cited 3×
“and clonal proliferations [3–13].”
BackgroundJendro, M. C., Ganten, T., Matteson, E. L., Weyand, C. M., & Goronzy, J. J. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380912 · Cited by 97 · cited 1×
“Because the CD4CD28 lymphocytes are daughter progeny of repetitive, antigen-driven T-cell replication cycles [19,20,25,27,30,31], we anticipated these cells would be highly activated.”
BackgroundRole of the Chemokine Receptors CXCR3 and CCR4 in Human Pulmonary Fibrosis
Pignatti, P., Brunetti, G., Moretto, D., Yacoub, M.-R., Fiori, M., Balbi, B., Balestrino, A., Cervio, G., Nava, S., & Moscato, G. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200502-244oc · Cited by 91 · cited 2×
“and clonal proliferations [3–13].”
BackgroundHigh Prevalence of Circulating CD4+CD28−T-Cells in Patients With Small Abdominal Aortic Aneurysms
Duftner, C., Seiler, R., Klein-Weigel, P., Göbel, H., Goldberger, C., Ihling, C., Fraedrich, G., & Schirmer, M. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000167520.41436.c0 · Cited by 85
Lambers, C., Hacker, S., Posch, M., Hoetzenecker, K., Pollreisz, A., Lichtenauer, M., Klepetko, W., & Jan Ankersmit, H. (2009) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2008.03835.x · Cited by 75 · cited 10×
“These data demonstrate that the CD4CD28 T-cells of IPF patients exhibit unusual characteristics (Figure 1B and Figure 2) that are very similar to analogous cells isolated from other patient populations with chronic immunologic diseases [19–34].”
BackgroundResultInfluentialDobashi, N., Fujita, J., Murota, M., OHTSUKI, Y., Yamadori, I., Yoshinouchi, T., UEDA, R., Bandoh, S., Kamei, T., Nishioka, M., et al. (2000) · Lung · doi:10.1007/s004080000020 · Cited by 66 · cited 3×
“and clonal proliferations [3–13].”
BackgroundSynergy Between CD40 Ligation and IL-4 on Fibroblast Proliferation Involves IL-4 Receptor Signaling
Atamas, S. P., Luzina, I. G., Dai, H., Wilt, S. G., & White, B. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.3.1139 · Cited by 65 · cited 1×
“fibrogenesis [41], is a notable exception.”
Colombatti, A., Doliana, R., Schiappacassi, M., Argentini, C., Tonutti, E., Feruglio, C., & Sala, P. (1998) · Clinical Immunology and Immunopathology · doi:10.1006/clin.1998.4580 · Cited by 62 · cited 10×
“These data demonstrate that the CD4CD28 T-cells of IPF patients exhibit unusual characteristics (Figure 1B and Figure 2) that are very similar to analogous cells isolated from other patient populations with chronic immunologic diseases [19–34].”
BackgroundMethodResultInfluentialFontenot, A. P., Gharavi, L., Bennett, S. R., Canavera, S. J., Newman, L. S., & Kotzin, B. L. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18317 · Cited by 61 · cited 1×
“other costimulatory molecules can also provide the second signal necessary for initial activations of naı̈ve CD4 cells [38,39].”
BackgroundFontenot, A. P., Gharavi, L., Bennett, S. R., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318317 · Cited by 50
CD8+ T lymphocytes in bronchoalveolar lavage in idiopathic pulmonary fibrosis
Papiris, S. A., Kollintza, A., Karatza, M., Manali, E. D., Sotiropoulou, C., Milic‐Emili, J., Roussos, C., & Daniil, Z. D. (2007) · Journal of Inflammation · doi:10.1186/1476-9255-4-14 · Cited by 48
Localisation of a pulmonary autoantigen in cryptogenic fibrosing alveolitis.
Wallace, W. A., Schofield, J. A., Lamb, D., & Howie, S. (1994) · Thorax · doi:10.1136/thx.49.11.1139 · Cited by 46
Systemic Immune Cell Activation in a Subgroup of Patients with Idiopathic Pulmonary Fibrosis
Homolka, J., Ziegenhagen, M. W., Gaede, K. I., Entzian, P., Zissel, G., & Müller–Quernheim, J. (2003) · Respiration · doi:10.1159/000072007 · Cited by 40
The perforin mediated apoptotic pathway in lung injury and fibrosis
Miyazaki, H., Kuwano, K., Yoshida, K., Maeyama, T., Yoshimi, M., Fujita, M., Hagimoto, N., Yoshida, R., & Nakanishi, Y. (2004) · Journal of Clinical Pathology · doi:10.1136/jcp.2003.015495 · Cited by 39 · cited 1×
“Moreover, the perforin and granzyme B productions (Figure 1B) of the CD4CD28 lymphocytes could conceivably account for infiltrates of cytotoxic granule-laden lymphocytes that are present in IPF lungs [40] (Figure 6), and are believed to contribute to the pulmonary epithelial apoptosis of this disease [35].”
BackgroundOligoclonal CD4 + T Cell Expansions in Lung Transplant Recipients with Obliterative Bronchiolitis
Duncan, S. R., Leonard, C. T., Theodore, J., Lega, M., Girgis, R. E., Rosen, G., & Theofilopoulos, A. N. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2107009 · Cited by 38 · cited 1×
“. Alloantigens are often highly immunogenic, capable of evoking brisk, severe, and refractory allograft rejection, and are initially recognized by ≤10% of the recipient T-cell repertoire”
BackgroundSelf-citationCD28 Down-Regulation on CD4 T Cells Is a Marker for Graft Dysfunction in Lung Transplant Recipients
Studer, S. M., George, M. P., Zhu, X., Song, Y., Valentine, V. G., Stoner, M. W., Sethi, J. M., Steele, C. H., & Duncan, S. R. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200701-013oc · Cited by 30 · cited 10×
“Nevertheless, we have previously shown that freshly isolated CD4CD28 lymphocytes from lung transplant recipients are able to proliferate with TCR crosslinking [20], raising the possibility that the reported inability of CD4CD28 cell lines to divide is a consequence of their protracted in vitro propagation.”
BackgroundResultSelf-citationAutoantibody to alanyl‐tRNA synthetase in patients with idiopathic pulmonary fibrosis
Takahashi, T., Wada, I., Ohtsuka, Y., Munakata, M., Homma, Y., & Kuroki, Y. (2007) · Respirology · doi:10.1111/j.1440-1843.2007.01140.x · Cited by 28 · cited 3×
“and clonal proliferations [3–13].”
BackgroundShimizudani, N., 村田, 秀., Keino, H., Kojo, S., Nakamura, H., Morishima, Y., Sakamoto, T., Ohtsuka, M., Sekisawa, K., SUMIDA, M., et al. (2002) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2002.01871.x · Cited by 22 · cited 2×
“and clonal proliferations [3–13].”
BackgroundHirokawa, M., Horiuchi, T., Kawabata, Y., Kitabayashi, A., Saitoh, H., Ichikawa, Y., Matsutani, T., Yoshioka, T., Tsuruta, Y., Suzuki, R., et al. (2001) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1703045 · Cited by 11
Cited by
Travis, W. D., Costabel, U., Hansell, D. M., King, T. E., Lynch, D. A., Nicholson, A. G., Ryerson, C. J., Ryu, J. H., Selman, M., Wells, A. U., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201308-1483st · Cited by 4,290
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Martinez, F. J., Collard, H. R., Pardo, A., Raghu, G., Richeldi, L., Selman, M., Swigris, J. J., Taniguchi, H., & Wells, A. U. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.74 · Cited by 1,388
Selman, M., & Pardo, A. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201312-2221pp · Cited by 454
Molecular and cellular mechanisms of pulmonary fibrosis
Todd, N. W., Luzina, I. G., & Atamas, S. P. (2012) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-5-11 · Cited by 418
“These T cells are activated and antigen experienced [132,135,136], and characterization has shown that both CD4+ and CD8+ cells are present, with the suggestion that CD8+ T cells represent the majority [129-132,137].”
Background
Metadata
- Authors
- Gilani, S. R., Vuga, L. J., Lindell, K. O., Gibson, K. F., Xue, J., Kaminski, N., Valentine, V. G., Lindsay, E. K., George, M. P., Steele, C., & Duncan, S. R.
- Affiliations
- University of Pittsburgh (US)
- The University of Texas Medical Branch at Galveston (US)
- University of Alabama at Birmingham (US)
- Corresponding author
- Duncan, Steven R.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-01-29
- Volume
- 5
- Issue
- 1
- Pages
- e8959
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC2813297
- OpenAlex
- W1976574577
- Cited by
- 203
- References
- 54
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 15 · 2023: 14 · 2022: 11 · 2021: 12 · 2020: 9 · 2019: 9 · 2018: 18 · 2017: 14 · 2016: 11 · 2015: 14 · 2014: 13 · 2013: 18 · 2012: 18
- FWCI
- 13.56
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- D-Scholarship@Pitt (University of Pittsburgh) (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- University of Pittsburgh
- National Institutes of Health (5r01hl073241-04, 5p50hl084932-05)
- National Heart, Lung, and Blood Institute (R01 HL073241, P50-HL-084932, 1P50 HL084932, 1R01HL073241, T32HL007563)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- idiopathic pulmonary fibrosis, CD4+ T cells, T cell exhaustion, prognostic factors, perforin, granzyme B, Foxp3+ regulatory T cells, inflammatory cytokines, lung transplantation, forced vital capacity, adaptive immune activation, lung infiltration, major adverse clinical events, T cell activation markers
- MeSH terms
- Adult, Humans, Male, Prognosis, Pulmonary Fibrosis, CD4-Positive T-Lymphocytes, Down-Regulation, CD28 Antigens
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.